MEIP - MEI Pharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-49.41M

Cash

112M

Avg Qtr Burn

-14.17M

Short % of Float

3.57%

Insider Ownership

0.54%

Institutional Own.

39.34%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Voruciclib (CDK Inhibitor) Details B-cell malignancies, Acute myeloid leukemia, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ME-344 (Mitochondrial Inhibitor) Details Cancer, Solid tumor/s	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zandelisib (Oral P13K Delta Inhibitor) Details Follicular lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.